Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Stock Information for Amarin Corporation plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Amarin Corporation plc

Amarin Announces Two Upcoming Investor Events
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Amarin Board of Directors Announces CEO Transition
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.